Assessing the economic impact of psychiatric disorders: where to begin?
Over the past decade, psychiatric disorders have increasingly been regarded as serious public health concerns, with debilitating symptoms as well as high social and economic costs to patients, caregivers, third party payers and society. In this article, we review findings from recent research on psychiatric disorders, while providing a framework for assessing their pharmacoeconomic impact. In particular, we consider the prevalence of psychiatric disorders, their far-reaching impacts, and their associated treatment patterns. These categories present a starting point for analysing the pharmacoeconomic consequences of psychiatric disorders and underlie an expert opinion in this context
Greenberg
P E
PE
Analysis Group/Economics, One Brattle Square, Fifth Floor, Cambridge, MA 02138, USA. pgreenberg@analysisgroup.com
Leong
S A
SA
Birnbaum
H G
HG
D017850:Economics, Pharmaceutical; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy / Q000191:economics* / Q000453:epidemiology; D015995:Prevalence